Riamilovir

Riamilovir is an oral, broad-spectrum antiviral agent. Riamilovir can directly act on the virus's RNA-dependent RNA polymerase, thereby inhibiting viral replication, reducing viral load, and helping to alleviate the severity of the disease. Riamilovir can be used in research on acute respiratory viral infections caused by novel variants of SARS-CoV-2^[1]. In Vivo:Riamilovir (250 mg capsules, once daily; orally for 10 consecutive days) demonstrated broad-spectrum antiviral activity against influenza, tick-borne encephalitis, and SARS-CoV-2 in a randomized, double-blind, multicenter trial. It was able to reduce the viral load of SARS-CoV-2 in vivo without severe adverse reactions^[1].
Riamilovir (0.85 mg/kg; orally once daily for 7 consecutive days) produced a significant endothelial protective effect in male C57BL/6 mice with endothelial dysfunction induced by L-NAME. This substance reduced the levels of MMP-2 and MMP-9 in the aortic supernatant of mice by 20.4% and 19.5%, respectively, and downregulated the level of iNOS in the aorta by 57.2% and upregulated the level of eNOS by 40.0%^[2].